Dear Colleague,
Drs. Johan Gabrielsson and Daniel Weiner, two of the world's top experts in
PK/PD modeling, are teaching the 14th Advanced Level Workshop on
Pharmacokinetic - Pharmacodynamic Data
https://www.certara.com/training/classes/54. In this workshop, you'll
learn to apply advanced approaches for conducting PK/PD analysis on real life
case studies from discovery, preclinical and development. This course has
updated content including hands-on problem solving that will include an
introduction to population PK/PD modeling.
Registration Closes April 27th! Sign up today. Register
https://www.certara.com/training/classes/54.
Course date and location:
Maritim Hotel Munich, Munich, Germany from May 12-15, 2014
Topics include:
Dose-response-time analysis, advanced principles of turnover modeling including
modeling tolerance and rebound, approaches to TMDD modeling, approaches to
optimizing sampling collection times, modeling PD effects for combination drug
treatments, pattern recognition, and translational aspects of PK/PD modeling.
Course includes:[cid:[email protected]]
* Complimentary copy of Pharmacokinetic & Pharmacodynamic Data Analysis
[with CD-ROM]
* Lectures, group exercises with discussion, and hands-on PK/PD data
analysis including population PK/PD modeling using Phoenix WinNonlin and NLME
* Discussions and exercises will enable participants to master
state-of-the-art approaches to real-world problems
Who should attend:
Scientists with at least 5 years of experience in PK/PD modeling
Don't miss this opportunity to increase your confidence in understanding basic
and advanced approaches to PK/PD modeling and to apply these approaches using
population methods.
________________________________
Course Lecturers:
Johan Gabrielsson, PhD, Pharmacology Professor, Swedish Agricultural University
Dr. Gabrielson has taught numerous courses, leveraging industry experience in
kinetic/dynamic related projects at AstraZeneca R&D Mölndal to craft real world
examples. His research currently focuses on modeling different aspects of
endogenous turnover, such as functional tolerance and rebound phenomena,
physiological limits and target-mediated drug disposition.
Daniel Weiner, PhD, Senior Vice President, Thought Leadership and Client
Engagement
In addition to his tenure at Certara, Dr. Weiner has served as an expert
consultant to the U.S. Food and Drug Administration on pharmacokinetic modeling
and bioequivalence assessment. He has also held several senior management
positions both within pharma and the CRO industries. He is also currently an
Adjunct Associate Professor at the UNC School of Pharmacy.
Sincerely,
Alicia Holmes
Sales Support Specialist, Certara